

REVIEW OF DECISIONS

BOARD MEETING

15-17 December 2020, Virtual Meeting



Reach every child

www.gavi.org

Decision 1: Consent Agenda: Board and Committee member appointments (1/7)

The Gavi Alliance Board:

a) **Appointed** the following Board Members:

- **Joan Valadou** as Board Member representing France on the donor constituency cluster anchored by Germany in the seat currently held by Jan Paehler of the European Commission, effective 1 January 2021 and until 31 December 2021.
- **John Arne Røttingen** as Board Member representing Norway on the donor constituency cluster anchored by Norway in the seat currently held by Harriet Pedersen of Sweden, effective 1 January 2021 and until 31 December 2022.
- **Megan Cain** as Board Member representing Canada on the donor constituency cluster anchored by Canada in the seat currently held by Francesca Manno of Italy, effective 1 January 2021 and until 31 December 2022.

Decision 1: Consent Agenda: Board and Committee member appointments (2/7)

- **Kwaku Agyeman-Manu** of Ghana as Board Member representing the implementing country constituency in the seat currently held by Lia Tadesse of Ethiopia, effective 1 January 2021 and until 31 December 2023.
- **Harsh Vardhan** of India as Board Member representing the implementing country constituency in the seat currently held by Myint Htwe of Myanmar, effective 1 January 2021 and until 31 December 2023.
- **Assad Hafeez** of Pakistan as Board Member representing the implementing country constituency in the seat currently held by Ahmad Jawad Osmani of Afghanistan, effective 1 January 2021 and until 31 December 2023.

Decision 1: Consent Agenda: Board and Committee member appointments (3/7)

b) **Reappointed** the following Board Members:

- **Marta Nunes** as Board Member representing the research & technical health institutes constituency, effective 1 January 2021 and until 31 December 2023.

c) **Appointed** the following Alternate Board Members:

- **Bernhard Braune** as Alternate Board Member representing Germany on the donor constituency cluster anchored by Germany in the seat currently held by Joan Valadou of France, effective 1 January 2021 and until 31 December 2021.
- **Hannah Haaij** as Alternate Board Member representing the Netherlands on the donor constituency cluster anchored by Norway in the seat currently held by Noor Khan of Norway, effective 1 January 2021 and until 31 December 2022.

Decision 1: Consent Agenda: Board and Committee member appointments (4/7)

- **Francesca Manno** as Alternate Board Member representing Italy on the donor constituency cluster anchored by Canada in the seat currently held by Megan Cain of Canada, effective 1 January 2021 and until 31 December 2022.
- **Lia Tadesse** of Ethiopia as Alternate Board Member representing the implementing country constituency in the seat currently held by Kwaku Agyeman-Manu of Ghana, effective 1 January 2021 and until 31 December 2023.
- **Ahmad Jawad Osmani** of Afghanistan as Alternate Board Member representing the implementing country constituency in the seat currently held by Assad Hafeez of Pakistan, effective 1 January 2021 and until 31 December 2023.
- **Saad Omer** as Alternate Board Member to Marta Nunes representing the research and technical health institutes constituency in the seat currently held by William Schluter, effective 1 January 2021 and until 31 December 2023.

Decision 1: Consent Agenda: Board and Committee member appointments (5/7)

- d) **Reappointed** the following Alternate Board Member:
- **Boukong Syhavong** of Lao PDR as Alternate Board member to Harsh Vardhan representing the implementing country constituency, effective 1 January 2021 and until 31 December 2023.
- e) **Appointed** the following to the Market-Sensitive Decisions Committee effective 1 January 2021:
- **José Manuel Barroso** (Board Chair) until 31 December 2021
 - **Joan Valadou** (Board Member) until 31 December 2021
- f) **Reappointed** the following to the Market-Sensitive Decisions Committee effective 1 January 2021:
- **Lia Tadesse** (Alternate Board Member) until 31 December 2021

Decision 1: Consent Agenda: Board and Committee member appointments (6/7)

- g) **Appointed** the following to the Governance Committee effective 1 January 2021:
- **Assad Hafeez** (Board Member) until 31 December 2021
 - **Joan Valadou** (Board Member) until 31 December 2021
- h) **Reappointed** the following to the Governance Committee effective 1 January 2021:
- **Megan Cain** (Board Member) until 31 December 2021
- i) **Reappointed** the following to the Audit and Finance Committee effective 1 January 2021:
- **Kwaku Agyeman-Manu** (Alternate Board Member) until 31 December 2021
- j) **Appointed** the following to the Investment Committee effective 1 January 2021:
- **Kwaku Agyeman-Manu** (Alternate Board Member) until 31 December 2021
-

Decision 1: Consent Agenda: Board and Committee member appointments (7/7)

- k) **Appointed** the following to the Programme and Policy Committee effective 1 January 2021:
- **Bernhard Braune** (Alternate Board Member) until 31 December 2021
 - **Karin Westerberg** (Committee Delegate) until 31 December 2021
- l) **Reappointed** the following to the Programme and Policy Committee effective 1 January 2021:
- **William Schluter** (Committee Delegate) until 31 December 2021
- m) **Reappointed** the following to the Evaluation Advisory Committee effective 1 January 2021:
- **Marta Nunes** (Board Member) until 31 December 2021

Decision 2: Consent Agenda: Independent Review Committee appointments

The Gavi Alliance Board:

- a) **Appointed** as new IRC members the individuals listed in Annex A to Doc 01f with terms effective 17 December 2020 and until 31 March 2024; and
- b) **Approved** the extension of the terms of the IRC members listed in Annex B to Doc 01f for a further three-year term until 31 March 2024.

Decision 3: Consent Agenda: Review of Annexes to Operating Procedures

The Gavi Alliance Board:

- a) **Approved** the amendments to the Annexes to the Board and Board Committee Operating Procedures attached as Annexes C, D, E, F, G, H, I, J, K L, M and N to Doc 01f;
- b) **Authorised** the Secretary to arrange for all other Board-approved policies, charters, terms of reference and similar documents to be updated as required to update references to the Statutes and Board and Board Committee Operating Procedures and to approve the updated documents; and
- c) **Noted** that pending b) above the documents being updated should be read and construed as though the changes have been made.

Decision 4: Consent Agenda: COVAX Facility Terms of Reference

The Gavi Alliance Board:

- a) **Approved** the Terms of Reference of the COVAX Shareholders Council attached as Annex O to Doc 01f, as amended by discussions at the Governance Committee;
- b) **Approved** the Terms of Reference of the COVAX Consensus Group attached as Annex P to Doc 01f;
- c) **Approved** the Terms of Reference of the COVAX AMC Engagement Group attached as Annex Q to Doc 01f, as amended by discussions at the Governance Committee; and
- d) **Approved** the Terms of Reference of the COVAX AMC Investors Group attached as Annex R to Doc 01f, as amended by discussions at the Governance Committee.

Decision 5: Consent Agenda: Programme Funding Policy

The Gavi Alliance Board:

Approved the amendments to the Programme Funding Policy, attached as Annex S to Doc 01f, related to the consideration of Partners' Engagement Framework Targeted Country Assistance, Strategic Focus Areas and Foundational Support as multi-year programmatic support and multi-year approval for programmes as detailed in Annex T to Doc 01f.

Decision 6: Consent Agenda: Stockpiles

The Gavi Alliance Board:

- a) **Approved** the extension of Gavi support for use of the global cholera stockpile in endemic settings through 2022;
- b) **Authorised** the Secretariat, under the Programme Funding Policy, to (i) allot US\$ 13.3 million in funding to the global cholera stockpile based on a financial forecast endorsed by the Board, (ii) allot funding to extend budgets to future years and/or (iii) adjust annual budget amounts as authorised by the CEO/ DCEO taking into account updated timing of implementation and budget utilisation; and
- c) **Approved** the pre-emptive use of vaccine doses from the International Coordinating Group (ICG) meningitis emergency stockpile as a last resort, which are nearing their expiry dates (determined on the basis of the mechanism set out in this paper), noting that there are no additional financial implications to Gavi beyond the costs of the doses, devices and corresponding freight and insurance already reflected in the financial forecast.

Decision 7: Consent Agenda: Gavi 5.0: Measurement Framework

The Gavi Alliance Board **approved** the proposed mission and strategy performance indicators attached as Annex C to Doc 01g, noting that:

- a) Operational definitions for a small number of indicators are pending finalisation within the Immunisation Agenda 2030 M&E Framework, to which the Gavi 5.0 Measurement Framework wishes to align wherever possible; and
- b) Indicators on geographic equity, as well as the five drivers of SG2 will require time to obtain meaningful data to report to the Board at portfolio level.

Decision 8: Financial Update, Including forecast

The Gavi Alliance Board:

- a) **Noted** that the Audit and Finance Committee has reviewed the financial implications of the recommendations to be made to the Programme and Policy Committee as set out in Figure 1 of Doc 02a and concluded that these recommendations could be approved by the Board in accordance with the Programme Funding Policy;
- b) **Approved** the updated Financial Forecast for the period 2016-2020 as set out in Section B of Doc 02a;
- c) **Approved** the Financial Forecast for the period 2021-2025 as set out in Section B of Doc 02a, which is dependent on resources becoming available for that period; and
- d) **Authorised** the Gavi Secretariat to allot funding in 2021 for new programmes and for the continuation and adjustment of funding to existing programmes, in accordance with the Programme Funding Policy.

Decision 9: Partners' Engagement Framework & Secretariat Budget 2021-2022 (1/2)

The Gavi Alliance Board:

- a) **Noted** that the budget for Vaccine, CCEOP and Surveillance equipment Procurement fees for 2022 is provisional and will be presented for Board approval once the MoU9 discussions are concluded;
 - b) **Approved**, within the overall amount of US\$ 252.5 million for 2021 and US\$ 249.8 million for 2022 for the Partners' Engagement Framework, the following allocations:
 - i. US\$ 175.2 million each year for PEF Targeted Country Assistance, Special Investments in Strategic Focus Areas and Foundational Support;
 - ii. US\$ 24.0 million each year for investing in Partnerships in Innovation to be administered by the Secretariat;
 - iii. US\$ 21.4 million each year for Impact Assessments and Evaluations.
-

Decision 9: Partners' Engagement Framework & Secretariat Budget 2021-2022 (1/2)

- c) **Approved** US\$ 128.5 million in 2021 and US\$ 132.7 million in 2022 for Secretariat Resources;
- d) **Approved** US\$ 1 million in 2021 and US\$ 0.5 million in 2022 for capital expenditure budgets; and
- e) **Noted** that further discussion of these amounts and budgets and further information will be provided through the Partners' Engagement Framework Management Team (PEF MT), Programme and Policy Committee (PPC) and HR (Human Resources) Subcommittee of the Governance Committee and further discussions between Secretariat and Alliance partners will take place to underpin these decisions.

Decision 10: Accelerating Efforts to Reach Zero-Dose Children and Missed Communities in Gavi 5.0 (1/3)

The Gavi Alliance Programme and Policy Committee, recognised:

1. The importance of equity and urgency of making available additional support to countries to maintain, restore and strengthen immunisation and reach zero-dose and under-immunised children;
2. The dynamic nature of the current COVID-19 pandemic and the increased risk of outbreaks and spike in child deaths;
3. The need for further work across the Alliance to operationalise the approach to reach zero-dose children, bringing together all the levers of Gavi support including HSS and PEF;
4. Uncertainty around the cost of reaching zero-dose children and missed communities, and hence the need for flexibility in the Alliance's approach and investments; and
5. The need for further discussion at the PEF Management Team on how PEF funding will be allocated in Gavi 5.0, noting the increased needs of WHO and UNICEF at global and regional levels in the context of Covid-19 and the importance of deepening subnational engagement with context appropriate partnerships, especially in fragile countries and to support the equity agenda.

Decision 10: Accelerating Efforts to Reach Zero-Dose Children and Missed Communities in Gavi 5.0 (2/3)

Identified a number of areas (outlined in Annex B to the October 2020 meeting decisions) upon which the Secretariat should provide further clarification in the December 2020 Board paper.

The PPC also underscored the need for flexibility and asked the Secretariat to monitor implementation of the following decision and report back to the PPC on operationalisation of this decisions and any adjustments in resources or approach that might be required over the course of Gavi 5.0.

Decision 10: Accelerating Efforts to Reach Zero-Dose Children and Missed Communities in Gavi 5.0 (3/3)

Subsequently, the Gavi Alliance Board:

- a) **Approved** an additional US\$ 500 million in health system strengthening (HSS) for the strategic period 2021-2025 as dedicated funding for zero-dose children and missed communities. This amount is in addition to the US\$ 1.2 billion in HSS included in the forecast presented and previously approved by the Board at its July 2020 meeting;
- b) **Approved** an increase in Partners' Engagement Framework (PEF) spending of US\$128 million to support efforts to reach zero-dose children and missed communities. This amount is in addition to the funding amounts included in the forecast presented and previously approved by the Board at its July 2020 meeting; and
- c) **Approved** US\$ 25 million in bridge funding for 2021 for fiduciary risk assurance and financial management capacity building, noting that a full strategy and associated funding request will be brought to the May 2021 PPC meeting.

Decision 11: Risk Management Update

The Gavi Alliance Board:

Approved the Risk & Assurance Report 2020 attached as Annex A to Doc 06.

Decision 12: Gavi's Approach to Engagement with Former and Never-Eligible Middle-Income Countries (1/2)

The Gavi Alliance Board:

- a) **Approved** the objectives of the Middle-Income Countries (MICs) Approach, namely
 - (i) to prevent backsliding in vaccine coverage in former Gavi-eligible countries, and
 - (ii) to drive the sustainable introduction of key missing vaccines in both former and select never Gavi-eligible countries;
- b) **Noting** that the Board has already approved (in June 2019) the inclusion of former Gavi-eligible countries in the scope of eligibility for the MICs Approach, **approved** the inclusion of never Gavi-eligible LMICs (<US\$ 4,000 GNI p.c.) and all other never Gavi-eligible World Bank IDA-eligible economies in the scope of eligibility for the MICs Approach;
- c) **Approved** the funding envelope of US\$ 281 million for the MICs Approach during the period of Gavi 5.0, i.e. from January 2021 to December 2025;

Decision 12: Gavi's Approach to Engagement with Former and Never-Eligible Middle-Income Countries (2/2)

- d) **Approved** the proposal for 'initial engagement', as described in Annex B to Doc 07, from January 2021 to June 2022, accounting for up to 25% of the total MICs funding envelope, noting that additional proposals to deliver on the full MICs Approach will be brought for Board approval in June 2022, along with a review of the inclusion of non-IDA eligible, never Gavi-eligible UMICs <US\$ 6,000 GNI p.c. into the MICs Approach.
- e) **Approved** extending the time period from until December 2020 to until June 2022 for use of the US\$ 20 million for targeted support previously approved by the Board (June 2020) for former Gavi-eligible countries to strengthen political will and address an identified risk of reduction in coverage rates of vaccines introduced with Gavi support in that country.

Decision 13: COVAX Facility Operationalisation and Vaccine Programme (1/2)

The Gavi Alliance Board:

- a) **Approved** the creation of the COVAX Buffer with the dual purpose to (i) ensure access to COVID-19 vaccines for high-risk populations in humanitarian settings and (ii) provide a contingency provision to enable an emergency release of doses to meet public health needs where normal vaccine allocation timelines may not be sufficient, subject to review of the Programme and Policy Committee in early 2021 and return to the Board if necessary;
- b) **Approved** the six organising principles of the COVAX Buffer of equitable access, targeted deployment, measure of last resort, contextual parity, alignment with overarching principles of COVAX and, in addition for the humanitarian element, adherence to the humanitarian principles;

Decision 13: COVAX Facility Operationalisation and Vaccine Programme (2/2)

- c) **Noted** that the total size of the Buffer, to cover both purposes, could be a real-time allocation of up to 5% of doses procured through the COVAX Facility;
- d) **Noted** that critical aspects regarding any remaining high-level parameters of the Buffer will be brought back to the PPC and Board for approval in 2021 as necessary;
- e) **Approved** US \$150 million to provide exceptional support, if required and on a case-by-case basis, to AMC92 participants to address critical vaccine delivery gaps for which no other funding is available, subject to this funding being mobilised by Gavi; and
- f) **Noted** the Reporting Framework.

Decision 14: COVAX Facility Operationalisation and Vaccine Programme

The Gavi Alliance Board:

Approved an Office of the COVAX Facility Budget of US \$55 million for 2021.

Decision 15: COVAX AMC Support to India

The Gavi Alliance Board:

Approved the proposed (high range) package of support for India as described in Annex A to Doc 10 providing 20% of total AMC doses and 20% of the overall amount provided for urgent TA and Cold Chain Equipment (CCE), subject to vaccine prices and available funds and to periodic review.

Thank you

